Roth Capital affirms Fibrocell Science, Inc. (Nasdaq: FCSC) at Buy with a price target of $5 after the company announced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Wedbush Remains Sidelined on Fibrocell Science (FCSC) Following Azficel-T Program Failure June 9, 2016 8:47 AM Fibrocell Science (FCSC) Reports Azficel-T Phase 2 in Vocal Cord Scarring Missed Primary EndpointsJune 8, 2016 8:04 AM Form 8-K Fibrocell Science, Inc. For: Jun 08June 8, 2016 8:03 AM Fibrocell Reports Phase II azficel-T Trial for Treatment of Vocal Cord Scarring Did Not Meet Primary EndpointsJune 8, 2016 8:01 AM Fibrocell Science (FCSC) halted with news pendingJune 8, 2016 7:55 AM